Placenta Safe™ Plus

Non-invasive prenatal test (NIPT) to assess the risk of trisomies 21, 18, and 13, as well as aneuploidies of the X and Y chromosomes, aneuploidies of chromosomes 9 and 16, and 6 microdeletion syndromes. Upon request, the fetal sex can be determined. In the case of twin pregnancy, it can be determined if at least one fetus has a Y chromosome.

Test scope:

• Trisomies of chromosomes 21, 18, 13
• Aneuploidies of X, Y chromosomes
• Trisomies of chromosomes 9, 16
• 6 syndromes associated with specific microdeletions:
  • DiGeorge (22q11.2 del)
  • Cri-du-chat (5p15.2 del)
  • Angelman (15q11.2-q13.1 del)
  • Prader-Willi (15q11.2-q13.1 del)
  • 1p36 deletion syndrome
  • Wolf-Hirschhorn (4p16.3 del)
• Fetal sex: The fetal sex is determined; in the case of twin pregnancy, it is determined if at least one fetus has a Y chromosome (male).

In the case of twin dichorionic pregnancy: Microdeletions and sex chromosome aneuploidies are not determined.

Recommendation from when to perform the test: Single and twin - from 10 weeks of pregnancy.

Sample: blood.

Execution time after arrival at the laboratory: 5-8 working days.